Mendelian randomization: Potential use of genetics to enable causal inferences regarding HIV-associated biomarkers and outcomes

Weijing He, John Castiblanco, Elizabeth A Walter, Jason F. Okulicz, Sunil K Ahuja

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose of Review: It is unknown whether biomarkers simply correlate with or are causal for HIV-associated outcomes. Mendelian randomization is a genetic epidemiologic approach used to disentangle causation from association. Here, we discuss the potential use of Mendelian randomization for differentiating whether biomarkers are correlating with or causal for HIV-associated outcomes. Recent Findings: Mendelian randomization refers to the random allocation of alleles at the time of gamete formation. In observational epidemiology, this refers to the use of genetic variants to estimate a causal effect between a modifiable risk factor and an outcome of interest. A formal Mendelian randomization study using a genetic marker as a proxy for the biomarker has not been conducted in the HIV field. However, in the postgenomic era, this approach is being used increasingly. Examples are evidence for the causal role of BMI in blood pressure and noncausal role of C-reactive protein in coronary heart disease. We discuss the conceptual framework, uses, and limitations of Mendelian randomization in the context of HIV infection as well as specific biomarkers (IL-6, C-reactive protein) and genetic determinants (e.g., in CCR5, chemokine, and DARC genes) that associate with HIV-related outcomes. Summary: Making the distinction between correlation and causality has particular relevance when a biomarker (e.g., IL-6) is potentially modifiable, in which case a biomarker-guided targeted treatment strategy may be feasible. Although the tenets of Mendelian randomization rest on strong assumptions, and conducting a Mendelian randomization study in HIV infection presents many challenges, it may offer the potential to identify causal biomarkers for HIV-associated outcomes.

Original languageEnglish (US)
Pages (from-to)545-559
Number of pages15
JournalCurrent Opinion in HIV and AIDS
Volume5
Issue number6
DOIs
StatePublished - Nov 2010

Fingerprint

Random Allocation
Biomarkers
HIV
Causality
C-Reactive Protein
HIV Infections
Interleukin-6
Proxy
Genetic Markers
Chemokines
Germ Cells
Coronary Disease
Epidemiology
Alleles
Blood Pressure
Genes

Keywords

  • Biomarker
  • chemokine
  • gene
  • HIV
  • Mendelian randomization

ASJC Scopus subject areas

  • Hematology
  • Oncology(nursing)
  • Immunology
  • Infectious Diseases
  • Virology
  • Oncology

Cite this

Mendelian randomization : Potential use of genetics to enable causal inferences regarding HIV-associated biomarkers and outcomes. / He, Weijing; Castiblanco, John; Walter, Elizabeth A; Okulicz, Jason F.; Ahuja, Sunil K.

In: Current Opinion in HIV and AIDS, Vol. 5, No. 6, 11.2010, p. 545-559.

Research output: Contribution to journalArticle

He, Weijing ; Castiblanco, John ; Walter, Elizabeth A ; Okulicz, Jason F. ; Ahuja, Sunil K. / Mendelian randomization : Potential use of genetics to enable causal inferences regarding HIV-associated biomarkers and outcomes. In: Current Opinion in HIV and AIDS. 2010 ; Vol. 5, No. 6. pp. 545-559.
@article{0230bdee51b84809ac39ba06ee54b375,
title = "Mendelian randomization: Potential use of genetics to enable causal inferences regarding HIV-associated biomarkers and outcomes",
abstract = "Purpose of Review: It is unknown whether biomarkers simply correlate with or are causal for HIV-associated outcomes. Mendelian randomization is a genetic epidemiologic approach used to disentangle causation from association. Here, we discuss the potential use of Mendelian randomization for differentiating whether biomarkers are correlating with or causal for HIV-associated outcomes. Recent Findings: Mendelian randomization refers to the random allocation of alleles at the time of gamete formation. In observational epidemiology, this refers to the use of genetic variants to estimate a causal effect between a modifiable risk factor and an outcome of interest. A formal Mendelian randomization study using a genetic marker as a proxy for the biomarker has not been conducted in the HIV field. However, in the postgenomic era, this approach is being used increasingly. Examples are evidence for the causal role of BMI in blood pressure and noncausal role of C-reactive protein in coronary heart disease. We discuss the conceptual framework, uses, and limitations of Mendelian randomization in the context of HIV infection as well as specific biomarkers (IL-6, C-reactive protein) and genetic determinants (e.g., in CCR5, chemokine, and DARC genes) that associate with HIV-related outcomes. Summary: Making the distinction between correlation and causality has particular relevance when a biomarker (e.g., IL-6) is potentially modifiable, in which case a biomarker-guided targeted treatment strategy may be feasible. Although the tenets of Mendelian randomization rest on strong assumptions, and conducting a Mendelian randomization study in HIV infection presents many challenges, it may offer the potential to identify causal biomarkers for HIV-associated outcomes.",
keywords = "Biomarker, chemokine, gene, HIV, Mendelian randomization",
author = "Weijing He and John Castiblanco and Walter, {Elizabeth A} and Okulicz, {Jason F.} and Ahuja, {Sunil K}",
year = "2010",
month = "11",
doi = "10.1097/COH.0b013e32833f2087",
language = "English (US)",
volume = "5",
pages = "545--559",
journal = "Current Opinion in HIV and AIDS",
issn = "1746-630X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Mendelian randomization

T2 - Potential use of genetics to enable causal inferences regarding HIV-associated biomarkers and outcomes

AU - He, Weijing

AU - Castiblanco, John

AU - Walter, Elizabeth A

AU - Okulicz, Jason F.

AU - Ahuja, Sunil K

PY - 2010/11

Y1 - 2010/11

N2 - Purpose of Review: It is unknown whether biomarkers simply correlate with or are causal for HIV-associated outcomes. Mendelian randomization is a genetic epidemiologic approach used to disentangle causation from association. Here, we discuss the potential use of Mendelian randomization for differentiating whether biomarkers are correlating with or causal for HIV-associated outcomes. Recent Findings: Mendelian randomization refers to the random allocation of alleles at the time of gamete formation. In observational epidemiology, this refers to the use of genetic variants to estimate a causal effect between a modifiable risk factor and an outcome of interest. A formal Mendelian randomization study using a genetic marker as a proxy for the biomarker has not been conducted in the HIV field. However, in the postgenomic era, this approach is being used increasingly. Examples are evidence for the causal role of BMI in blood pressure and noncausal role of C-reactive protein in coronary heart disease. We discuss the conceptual framework, uses, and limitations of Mendelian randomization in the context of HIV infection as well as specific biomarkers (IL-6, C-reactive protein) and genetic determinants (e.g., in CCR5, chemokine, and DARC genes) that associate with HIV-related outcomes. Summary: Making the distinction between correlation and causality has particular relevance when a biomarker (e.g., IL-6) is potentially modifiable, in which case a biomarker-guided targeted treatment strategy may be feasible. Although the tenets of Mendelian randomization rest on strong assumptions, and conducting a Mendelian randomization study in HIV infection presents many challenges, it may offer the potential to identify causal biomarkers for HIV-associated outcomes.

AB - Purpose of Review: It is unknown whether biomarkers simply correlate with or are causal for HIV-associated outcomes. Mendelian randomization is a genetic epidemiologic approach used to disentangle causation from association. Here, we discuss the potential use of Mendelian randomization for differentiating whether biomarkers are correlating with or causal for HIV-associated outcomes. Recent Findings: Mendelian randomization refers to the random allocation of alleles at the time of gamete formation. In observational epidemiology, this refers to the use of genetic variants to estimate a causal effect between a modifiable risk factor and an outcome of interest. A formal Mendelian randomization study using a genetic marker as a proxy for the biomarker has not been conducted in the HIV field. However, in the postgenomic era, this approach is being used increasingly. Examples are evidence for the causal role of BMI in blood pressure and noncausal role of C-reactive protein in coronary heart disease. We discuss the conceptual framework, uses, and limitations of Mendelian randomization in the context of HIV infection as well as specific biomarkers (IL-6, C-reactive protein) and genetic determinants (e.g., in CCR5, chemokine, and DARC genes) that associate with HIV-related outcomes. Summary: Making the distinction between correlation and causality has particular relevance when a biomarker (e.g., IL-6) is potentially modifiable, in which case a biomarker-guided targeted treatment strategy may be feasible. Although the tenets of Mendelian randomization rest on strong assumptions, and conducting a Mendelian randomization study in HIV infection presents many challenges, it may offer the potential to identify causal biomarkers for HIV-associated outcomes.

KW - Biomarker

KW - chemokine

KW - gene

KW - HIV

KW - Mendelian randomization

UR - http://www.scopus.com/inward/record.url?scp=78049262517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049262517&partnerID=8YFLogxK

U2 - 10.1097/COH.0b013e32833f2087

DO - 10.1097/COH.0b013e32833f2087

M3 - Article

C2 - 20978399

AN - SCOPUS:78049262517

VL - 5

SP - 545

EP - 559

JO - Current Opinion in HIV and AIDS

JF - Current Opinion in HIV and AIDS

SN - 1746-630X

IS - 6

ER -